FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048309908> ?p ?o ?g. }

• W2048309908 endingPage "705" @default.
• W2048309908 startingPage "695" @default.
• W2048309908 abstract "Background: Paget's disease of bone, the second most common metabolic bone disease in the United States, is characterized by localized areas of excessive bone resorption coupled with accelerated bone formation, resulting in new bone that is less structurally organized and is weaker than normal bone. Complications of Paget's disease can include bone pain, osteoarthritis, skeletal deformity, hearing loss, and fractures. The objective of this review is to provide a comprehensive overview of current standards of treatment in Paget's disease.Scope: A review of literature from 1974 to 2007 was performed on topics such as epidemiology, etiology, treatment of Paget's disease of bone, and bisphos­phonates.Findings: Paget's disease affects an estimated 2–7% of persons of age 55 years or older in North America and western Europe. Antiresorptive treatment with bisphos­phonates is the standard treatment, but there may be limitations to oral therapy. Intravenous pamidronate is efficacious and has long been available, but its use is hindered by an impractical recommended dosing regimen of 30 mg IV over 4 h for three consecutive days. In two identical, double-blind, 6-month trials, 96% of patients treated with a one-time intravenous treatment of zoledronic acid 5 mg achieved therapeutic response, compared with 74% treated with 60 days of daily oral treatment with risedronate 30 mg ( p < 0.001). One limitation of this review is that historical data are not reviewed in the same level of detail as newer treatments, because recent advances in pharmacotherapy of Paget's disease have reduced the clinical utility of the older drugs.Conclusion: The etiology of Paget's disease is unclear, but some evidence suggests genetic and viral com­ponents. Bisphosphonates restore normal bone turnover and relieve bone pain, but oral formulations may be limited by complicated dosing regimens and poor gastro­intestinal absorption. The bisphosphonate, zoledronic acid is administered as a single intravenous infusion and offers antiresorptive efficacy and longer-lasting remission." @default.
• W2048309908 created "2016-06-24" @default.
• W2048309908 creator A5029122417 @default.
• W2048309908 date "2008-01-25" @default.
• W2048309908 modified "2023-10-17" @default.
• W2048309908 title "A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg" @default.
• W2048309908 cites W166548755 @default.
• W2048309908 cites W1971365252 @default.
• W2048309908 cites W1971380382 @default.
• W2048309908 cites W1978701783 @default.
• W2048309908 cites W1983575260 @default.
• W2048309908 cites W1987690548 @default.
• W2048309908 cites W1999680191 @default.
• W2048309908 cites W2005728126 @default.
• W2048309908 cites W2008616216 @default.
• W2048309908 cites W2011308707 @default.
• W2048309908 cites W2011683420 @default.
• W2048309908 cites W2016415830 @default.
• W2048309908 cites W2018963990 @default.
• W2048309908 cites W2021563247 @default.
• W2048309908 cites W2024140662 @default.
• W2048309908 cites W2041703759 @default.
• W2048309908 cites W2041903928 @default.
• W2048309908 cites W2057905673 @default.
• W2048309908 cites W2060236520 @default.
• W2048309908 cites W2060281042 @default.
• W2048309908 cites W2064329452 @default.
• W2048309908 cites W2068204031 @default.
• W2048309908 cites W2074138272 @default.
• W2048309908 cites W2074890088 @default.
• W2048309908 cites W2075952681 @default.
• W2048309908 cites W2085234200 @default.
• W2048309908 cites W2092483322 @default.
• W2048309908 cites W2108958779 @default.
• W2048309908 cites W2114750368 @default.
• W2048309908 cites W2128778774 @default.
• W2048309908 cites W2129223584 @default.
• W2048309908 cites W2136023404 @default.
• W2048309908 cites W2142734448 @default.
• W2048309908 cites W2155681096 @default.
• W2048309908 cites W2169195257 @default.
• W2048309908 cites W2170205803 @default.
• W2048309908 cites W2326201416 @default.
• W2048309908 doi "https://doi.org/10.1185/030079908x260899" @default.
• W2048309908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18226324" @default.
• W2048309908 hasPublicationYear "2008" @default.
• W2048309908 type Work @default.
• W2048309908 sameAs 2048309908 @default.
• W2048309908 citedByCount "21" @default.
• W2048309908 countsByYear W20483099082012 @default.
• W2048309908 countsByYear W20483099082013 @default.
• W2048309908 countsByYear W20483099082014 @default.
• W2048309908 countsByYear W20483099082015 @default.
• W2048309908 countsByYear W20483099082016 @default.
• W2048309908 countsByYear W20483099082017 @default.
• W2048309908 countsByYear W20483099082018 @default.
• W2048309908 countsByYear W20483099082019 @default.
• W2048309908 countsByYear W20483099082020 @default.
• W2048309908 countsByYear W20483099082021 @default.
• W2048309908 countsByYear W20483099082022 @default.
• W2048309908 countsByYear W20483099082023 @default.
• W2048309908 crossrefType "journal-article" @default.
• W2048309908 hasAuthorship W2048309908A5029122417 @default.
• W2048309908 hasConcept C126322002 @default.
• W2048309908 hasConcept C141071460 @default.
• W2048309908 hasConcept C2776139714 @default.
• W2048309908 hasConcept C2776154862 @default.
• W2048309908 hasConcept C2776169692 @default.
• W2048309908 hasConcept C2776326535 @default.
• W2048309908 hasConcept C2776541429 @default.
• W2048309908 hasConcept C2779134260 @default.
• W2048309908 hasConcept C2781413609 @default.
• W2048309908 hasConcept C71924100 @default.
• W2048309908 hasConceptScore W2048309908C126322002 @default.
• W2048309908 hasConceptScore W2048309908C141071460 @default.
• W2048309908 hasConceptScore W2048309908C2776139714 @default.
• W2048309908 hasConceptScore W2048309908C2776154862 @default.
• W2048309908 hasConceptScore W2048309908C2776169692 @default.
• W2048309908 hasConceptScore W2048309908C2776326535 @default.
• W2048309908 hasConceptScore W2048309908C2776541429 @default.
• W2048309908 hasConceptScore W2048309908C2779134260 @default.
• W2048309908 hasConceptScore W2048309908C2781413609 @default.
• W2048309908 hasConceptScore W2048309908C71924100 @default.
• W2048309908 hasIssue "3" @default.
• W2048309908 hasLocation W20483099081 @default.
• W2048309908 hasLocation W20483099082 @default.
• W2048309908 hasOpenAccess W2048309908 @default.
• W2048309908 hasPrimaryLocation W20483099081 @default.
• W2048309908 hasRelatedWork W152294131 @default.
• W2048309908 hasRelatedWork W1966022737 @default.
• W2048309908 hasRelatedWork W2008551702 @default.
• W2048309908 hasRelatedWork W2031650256 @default.
• W2048309908 hasRelatedWork W2087919731 @default.
• W2048309908 hasRelatedWork W2138220544 @default.
• W2048309908 hasRelatedWork W2391683935 @default.
• W2048309908 hasRelatedWork W2413140691 @default.
• W2048309908 hasRelatedWork W2414407528 @default.
• W2048309908 hasRelatedWork W2469515091 @default.

• next